Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update

Onconetix, Inc. (NASDAQ:ONCO) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling 680,001 shares, a growth of 161.3% from the March 15th total of 260,259 shares. Approximately 104.8% of the company’s shares are short sold. Based on an average trading volume of 5,931,820 shares, the days-to-cover ratio is presently 0.1 days.

Onconetix Trading Down 10.7%

Shares of Onconetix stock opened at $1.09 on Friday. The business has a 50-day moving average price of $3.44 and a two-hundred day moving average price of $9.30. Onconetix has a 1-year low of $1.01 and a 1-year high of $74.29. The company has a market cap of $719,400.00, a P/E ratio of -0.01 and a beta of 3.63.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Onconetix stock. Pacific Capital Wealth Advisors Inc. bought a new position in Onconetix, Inc. (NASDAQ:ONCO) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned approximately 0.84% of Onconetix as of its most recent filing with the Securities and Exchange Commission (SEC). 23.89% of the stock is currently owned by institutional investors.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.